Abstract:Transmitted/founder (TF) simian-human immunodeficiency viruses (SHIVs) express HIV-1 envelopes modified at position 375 to efficiently infect rhesus macaques while preserving authentic HIV-1 Env biology. SHIV.C.CH505 is an extensively characterized virus encoding the TF HIV-1 Env CH505 mutated at position 375 shown to recapitulate key features of HIV-1 immunobiology, including CCR5-tropism, a tier 2 neutralization profile, reproducible early viral kinetics, and authentic immune responses. SHIV.C.CH505 is used frequently in nonhuman primate studies of HIV, but viral loads after months of infection are variable and typically lower than those in people living with HIV. We hypothesized that additional mutations besides Δ375 might further enhance virus fitness without compromising essential components of CH505 Env biology. From sequence analysis of SHIV.C.CH505-infected macaques across multiple experiments, we identified a signature of envelope mutations associated with higher viremia. We then used short-term in vivo mutational selection and competition to identify a minimally adapted SHIV.C.CH505 with just five amino acid changes that substantially improve virus replication fitness in macaques. Next, we validated the performance of the adapted SHIV in vitro and in vivo and identified the mechanistic contributions of selected mutations. In vitro , the adapted SHIV shows improved virus entry, enhanced replication on primary rhesus cells, and preserved neutralization profiles. In vivo , the minimally adapted virus rapidly outcompetes the parental SHIV with an estimated growth advantage of 0.14 days- 1 and persists through suppressive antiretroviral therapy to rebound at treatment interruption. Here, we report the successful generation of a well-characterized, minimally adapted virus, termed SHIV.C.CH505.v2, with enhanced replication fitness and preserved native Env properties that can serve as a new reagent for NHP studies of HIV-1 transmission, pathogenesis, and cure. The power of the nonhuman primate model of HIV to predict outcomes in people living with HIV (PLWH) depends on authentic virus-host interactions. In pursuit of viruses that generate infection that mirrors the effects of HIV-1 in PLWH, we developed a minimally adapted version of a commonly used virus, SHIV.C.CH505, which has better fitness than the parental virus while retaining important biological properties. First, we studied virus sequences from SHIV.C.CH505-infected rhesus macaques to identify a signature of mutations common to animals with higher viral loads. We then tested viruses containing the various mutations in the lab and in animals to determine the most fit version and to identify the contribution of each mutation. Ultimately, we identified a minimally adapted version of SHIV.C.CH505 with just 5 amino acid substitutions that enhances virus replication and preserves CH505 envelope properties, including sensitivity to clinically relevant broadly neutralizing antibodies. This new virus, called SHIV.C.CH505.v2 replicates well in macaques over time and persists through antiretroviral therapy. SHIV.C.CH505.v2 could be an important component of nonhuman primate studies of HIV prevention, therapy, and cure.

Efficient Repeated Low-Dose Intravaginal Infection with SHIVSF162p3 in Chinese-Origin Rhesus Macaques

Titration of a SHIV1157ipd3N4 Stock by Intravenous Inoculation of Chinese-Origin Rhesus Macaques

Molecularly Cloned SHIV-CN97001: a Replication-Competent, R5 Simian/human Immunodeficiency Virus Containing Env of a Primary Chinese HIV-1 Clade C Isolate.

Construction and Characterization of A New Simian/Human Immunodeficiency Viruses Clone Carrying an Env Gene Derived from A Crf07_bc Strain

Titration of a SHIVSF162p3 from Vital Stock by Intravenous Inoculation of Chinese - Origin Rhesus Macaques

Serial passage of clade C SHIV-XJ02170 in Chinese origin Rhesus macaques

Partial protection of SHIV-infected Chinese rhesus macaques against super-infection with heterologous SHIV isolate.

The Propagation and Evaluation of SHIVSF162P3Adapative Virus Stock in Chinese-Origin Rhesus Macaques

Comparison of viral burden and disease progression in Chinese-origin rhesus macaques infected with common experimentally applied chimeric virus: SHIV-1157ipd3N4, SHIV-162P3, or SHIV-KB9.

HIV vaccine candidates generate in vitro T cell response to putative epitopes in Chinese-origin rhesus macaques.

Acute Infection of Chinese Macaques by a CCR5-tropic SHIV Carrying a Primary HIV-1 Subtype B' Envelope.

Title Acute infection of chinese macaques by a CCR 5-tropic SHIVcarrying a primary HIV-1 subtype B ' envelope

Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques

Cross-protection against reinfection of simian-human immunodeficiency virus(SHIV)in Chinese macaques vaccinated with different types of SHIV

Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.

HIV-1 Vaccines Based on Replication-Competent Tiantan Vaccinia Protected Chinese Rhesus Macaques from Simian HIV Infection.

Impact of Recombinant VSV-HIV Prime, DNA-Boost Vaccine Candidates on Immunogenicity and Viremia on SHIV-Infected Rhesus Macaques

Infection of Rhesus Macaques by SIVmac239 Virus Inoculated Rectally

Adaptation of a transmitted/founder simian-human immunodeficiency virus for enhanced replication in rhesus macaques

Protection Against SHIV-KB9 Infection by Combining Rdna and Rfpv Vaccines Based on HIV Multiepitope and P24 Protein in Chinese Rhesus Macaques

Immune Responses and Viral Persistence in Simian/Human Immunodeficiency Virus SHIV.C.CH848-Infected Rhesus Macaques